Analysis of clinical indications and dosage regimen of canakinumab

Canakinumab (Canakinumab) is a recombinant humanized monoclonal antibody, trade name ILARIS. Its mechanism of action is to specifically target and neutralize interleukin-1β (IL-1β), thereby inhibiting the inflammatory response mediated by IL-1β. ILARIS has been approved for a variety of rare autoinflammatory diseases and some rheumatic diseases, and is suitable for children and adult patients. Its indications cover a wide range, and treatment needs to accurately adjust the dose according to the specific disease type, patient weight and response.

In terms of periodic fever syndromes,ILARIS is indicated for cryopyrin protein-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), both of which are part of the inflammatory disease spectrum and are common in adults and children 4 years and older. For these patients, the recommended weight-related dose is: 150 mg subcutaneously every 8 weeks for those weighing more than 40 kg, and 2 mg/kg every 8 weeks for those weighing between 15 and 40 kg. For patients with inadequate response, this can be increased to 3 mg/kg every 8 weeks.

In addition,ILARIS is also indicated for the treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS), hyperimmune globulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and familial Mediterranean fever (FMF), covering adults and children. These diseases often present with symptoms such as recurrent fever, abdominal pain, musculoskeletal pain, and rash. The recommended starting dose for the above three types of diseases is as follows: patients weighing more than 40 kg should receive a subcutaneous injection of 150 mg every 4 weeks. If the response is insufficient, it can be increased to 300 mg. >Once every 4 weeks ; for those weighing no more than 40 kg, the starting dose is 2 mg/kg once every 4 weeks and can be increased to 4 mg/kg every 4 weeks if necessary.

In rheumatic immune diseases,ILARIS is approved for the treatment of active Still's disease (AOSD), including adult-onset Still's disease, and systemic juvenile idiopathic arthritis (SJIA) in children 2 years of age and older. This disease is characterized by persistent high fever, rheumatoid arthritis, and systemic inflammation, and some patients do not respond well to traditional nonsteroidal anti-inflammatory drugs and glucocorticoids. For patients weighing 7.5 kg or more, the recommended dose is 4 mg/kg subcutaneously once every 4 weeks, up to a maximum of 300 mg.

ILARIS is also used to treat gout attacks in adults who are contraindicated, intolerant of, or have an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine, and who are not suitable for repeated use of glucocorticoids. The recommended dose for this indication is 150 mg subcutaneously. In patients requiring retreatment, at least 12 weeks should elapse between doses to avoid drug accumulation or risk of adverse reactions.

Before using ILARIS, a doctor with relevant clinical experience should evaluate the patient's underlying disease, infection risk and immune status. Potential infection symptoms, liver and kidney functions, and blood routine indicators need to be continuously monitored during treatment. Because IL-1β plays an important role in the body's defense mechanism, long-term blockade of its function may increase the risk of serious infections. For those with active tuberculosis, chronic infection, or receiving immunosuppressive treatment, the risks of drug use should be carefully assessed.

In summary, canakinumab, as a biological agent targeting the inflammatory pathway, provides a new treatment option for multiple rare inflammatory diseases and some autoimmune diseases. The dosage plan must be reasonably formulated based on the indications, patient weight and response status, and must be closely followed up by professionals during the treatment period to ensure maximum efficacy and safety.

Reference: https://www.drugs.com/search.php?searchterm=ILARIS&sources%5B%5D=professional